Meeting
2023 ASCO Annual Meeting
Evaluation of palbociclib in combination with topotecan and cyclophosphamide in pediatric patients with recurrent or refractory neuroblastoma.
Authors
Theodore Willis Laetsch
Division of Oncology, Children’s Hospital of Philadelphia, and Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
Theodore Willis Laetsch , Fariba Navid , Brenda Weigel , Elizabeth Fox , Douglas S. Hawkins , Jodi Ann Muscal , Katarzyna Alicja Juszczak-Kosela , Zhe Zhang , Margaret E Macy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Clinical Trial Registration Number
NCT03709680
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS10069)
DOI
10.1200/JCO.2023.41.16_suppl.TPS10069
Abstract #
TPS10069
Poster Bd #
373b
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Phase 2 study to evaluate palbociclib in combination with irinotecan and temozolomide in pediatric patients with recurrent or refractory Ewing sarcoma.
First Author: Theodore Willis Laetsch
Poster
2022 ASCO Annual Meeting
Phase I trial of lorlatinib in combination with topotecan/cyclophosphamide in children with ALK-driven refractory or relapsed neuroblastoma: A new approaches to neuroblastoma therapy consortium study.
First Author: Kelly C. Goldsmith
First Author: Stuart Cramer
Poster
2021 ASCO Annual Meeting
Low-dose metronomic topotecan and pazopanib in children with recurrent or refractory solid tumors: A C17 Canadian phase I trial (TOPAZ).
First Author: Arif Manji